NGM Biopharmaceuticals, Inc.
NGM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $59 | $73 | $152 | $147 |
| Short-Term Investments | $88 | $198 | $214 | $148 |
| Receivables | $0 | $8 | $5 | $6 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $9 | $10 | $8 | $7 |
| Total Curr. Assets | $156 | $289 | $379 | $308 |
| Property Plant & Equip (Net) | $7 | $11 | $14 | $15 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $2 | $4 | $1 | $1 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $3 | $4 | $7 | $5 |
| Total NC Assets | $12 | $19 | $23 | $21 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $169 | $307 | $402 | $329 |
| Liabilities | – | – | – | – |
| Payables | $3 | $8 | $5 | $10 |
| Short-Term Debt | $0 | $5 | $5 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $18 | $0 |
| Other Curr. Liab. | $17 | $34 | $33 | $33 |
| Total Curr. Liab. | $20 | $48 | $61 | $43 |
| LT Debt | $0 | $0 | $5 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $6 |
| Total NC Liab. | $0 | $14 | $5 | $6 |
| Other Liabilities | $0 | -$14 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $20 | $48 | $67 | $49 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$724 | -$582 | -$419 | -$299 |
| AOCI | $0 | -$0 | -$0 | $0 |
| Other Equity | $873 | $841 | $755 | $579 |
| Total Equity | $149 | $260 | $336 | $280 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $169 | $307 | $402 | $329 |
| Net Debt | -$59 | -$68 | -$141 | -$147 |